|| List of recent Antibodies-related patents
| Axmi218, axmi219, axmi220, axmi226, axmi227, axmi228, axmi229, axmi230 and axmi231 delta-endotoxin genes and methods for their use|
Compositions and methods for conferring pesticidal activity to bacteria, plants, plant cells, tissues and seeds are provided. Compositions comprising a coding sequence for a toxin polypeptide are provided.
| Method for the purification of antibodies|
A method for the purification of immunoglobulins by ion exchange chromatography is described. The chromatographic method uses a weak ion exchange resin and a single step elution process for the purification of an immunoglobulin.
| Method of screening antibodies with high antigen selectivity|
Provided is a method of screening a target-specific antibody for an antigen that undergoes structural change in a particular physiological condition.. .
| Bispecific antibody|
Provided are bispecific antibodies comprised of a single-chain unit having specificity to an immune cell and a monovalent unit having specificity to a tumor cell or a microorganism. The single-chain unit includes a single-chain variable fragment (scfv) fused to an fc fragment and the monovalent unit includes a light chain and heavy chain pair.
| Antibodies comprising chimeric constant domains|
Antibodies, antigen-binding proteins and fc-fusion proteins that comprise recombinant polypeptides containing a chimeric heavy chain constant region sequence are provided that bind to certain fc receptors however have reduced effector functions. Methods of making constructs for expression of such chimeric fc-containing antibodies, antigen-binding proteins and fc-fusion proteins in cell systems, and methods of producing and isolating the chimeric fc-containing proteins are provided..
| Peptide biomarkers of cardiovascular disease|
The presently-disclosed subject matter provides methods for diagnosing a cardiovascular disease in a subject by determining an amount of one or more peptide biomarkers disclosed herein in a biological sample from the subject. The presently-disclosed subject matter further provides methods for determining treatment efficacy and/or progression of a cardiovascular disease in a subject by measuring amounts of one or more of the biomarkers in a biological sample from the subject.
| Antibodies to modified human igf-1/e peptides|
High-specificity antibodies can distinguish between modified (e.g, higf-1/ea 3mut) and endogenous wild-type human igf-1 proteins. These antibodies have little or no cross-reactivity with higf-1 or higf-2.
| High-throughput system and method for identifying antibodies having specific antigen binding activities|
System and methods are disclosed for identifying and isolating antibodies with specific affinity with an antigen of interest. Multiple dna libraries encoding antibodies or their fragments are designed such that the encoded antibodies from different libraries are tagged differently.
| Method for diagnosing alzheimer's disease (ad)|
Disclosed is a method for diagnosing alzheimer's disease (ad) wherein aβ-specific antibodies in a biological sample of a person that is suspected of having ad are detected comprising the following steps: —contacting the sample with aβ-aggregates or with particles having aβ-aggregate like surfaces and allowing the aβ-specific antibodies to bind to the aβ-aggregates, and —detecting the aβ-specific antibodies bound to the aβ-aggregates by a single particle detection technique, preferably by fluorescence activated cell sorting (facs); and wherein the amount of aβ-specific antibodies detected is compared with the amount in a sample of known ad status.. .
| Methods for detecting symmetrical dimethylarginine|
Method of detecting symmetrical dimethyl arginine (sdma) in biological samples. Sdma analogs for generating anti-sdma antibodies having little or no cross-reactivity with asymmetrical dimethyl arginine, arginine, and monomethylarginine.
| Artificial introns|
The invention concerns the field of recombinant gene engineering. It concerns novel artificial introns and compositions comprising such introns as well as a method to improve expression of polypeptides from nucleic acids such as cloned genes, especially genes encoding antibodies and antibody derived fragments, and the production of various polypeptides in eukaryotic host cells using said novel artificial intron sequences..
| Equine parasite detection|
The present invention provides a method of diagnosing a cyathostomin infection, said method comprising the step of identifying a level of anti-cyathostomin larval antigen antibodies in a sample, wherein a level of anti-cyathostomin larval antigen antibodies is indicative of a cyathostomin infection.. .
| Ritalinic acid immunoassay|
The invention provides novel antibodies which specifically bind to the methylphenidate metabolite, ritalinic acid, enabling an immunoassay that can detect methyphenidate in biological samples for an extended period following its ingestion. The invention also describes novel conjugates and kits incorporating the antibodies..
| Immunoassay for detecting kratom, its constituents and their use|
The invention relates to the field of drug detection and describes antibody-based components methods and kits for the detection and quantification of alkaloids of the plant kratom. The invention is underpinned by novel antibodies which specifically bind to mitragynine alkaloids found in the kratom plant and their metabolites..
| Predicting tumor response to anti-erbb3 antibodies|
A diagnostic method for predicting quantitatively whether a human tumor will be sensitive or resistant to treatment with an erbb3 inhibitor, e.g, an anti-erbb3 antibody, is disclosed. The method is based on measurement of nrg1 expression at the rna level, or at the protein level, in a tissue sample from the tumor..
| Method of diagnosing and preventing pneumococcal diseases using pneumococcal neuraminidases|
A method of providing protection against pneumococcal infection in a subject is disclosed. The method includes steps of administering to the subject a composition that includes combination of three recombinant pneumococcal neuraminidases: nana, nanb, and nanc of s.
| Methods and compositions for the generation and use of conformation-specific antibodies|
The present invention features methods and compositions for the generation of conformation-specific antibodies.. .
| Antibodies and antibody fragments targeting sirp-alpha and their use in treating hematologic cancers|
The invention relates to modulating the sirpα—cd47 interaction in order to treat hematological cancer and compounds therefor. In particular, there is also provided sirpα antibodies and antibody fragments, preferably used for treating hematological cancer..
| Methods for the treatment of il-1beta related conditions|
Disclosed are methods and materials for inhibiting (e.g., treating or preventing) uveitis in a subject, including treatment refractory uveitis, using anti-il-1β binding molecules (e.g., il-1β binding antibodies or binding fragment thereof).. .
| Polynucleotides encoding signal peptide-containing molecules|
The invention provides human signal peptide-containing proteins (hspp) and polynucleotides which identify and encode hspp. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists.
| Anti-mcsp antibodies|
The invention provides anti-mcsp antibodies and methods of using the same.. .
| Antibody variants and uses thereof|
Described herein are polypeptides and related antibodies comprising a variant fc domain. The variant fc domain provide for stabilized fc:fc interactions when the polypeptide(s), antibody or antibodies are bound to its target, antigen or antigens on the surface of a cell, thus providing for improved effector functions, such as cdc-response..
| Anti-icam-1 antibodies to treat multiple-myeloma related disorders|
The invention relates to the use of an antibody or an antigen-binding fragment thereof with binding specificity for icam-1, or a variant, fusion or derivative of said antibody or an antigen-binding fragment with binding specificity for icam-1, for the treatment of a multiple-myeloma-related disorder. The invention also relates to methods for the administration of such antibodies, fragments, variants, fusion and derivatives thereof..
| M-csf specific monoclonal antibody and uses thereof|
M-csf-specific rx1-based or rx-1 derived antibodies are provided, along with pharmaceutical compositions containing such antibody, kits containing a pharmaceutical composition, and methods of preventing and treating bone loss in a subject afflicted with an osteolytic disease.. .
| Frizzled 2 as a target for therapeutic antibodies in the treatment of cancer|
Disclosed herein are methods of treating cancer in a subject, and methods for inhibiting growth, migration and/or invasion of a cancer cell in the subject, comprising administering to the subject a therapeutically effective amount of an antibody or antigen binding fragment thereof that downmodulates fzd2. The antibody may specifically bind fzd2, and may promote internalization of the fzd2 receptor by the cancer cells and/or prevent ligand binding to fzd2.
| Jaml specific binding agents, antibodies, and uses related thereto|
Disclosed are specific binding agents such as antibodies and chimera that bind to jam-like protein. Also disclosed are heavy chain fragments, light chain fragments, and cdrs of the antibodies, as well as methods related thereto..
| Alpha-synuclein antibodies and uses thereof|
The invention describes antibodies having a high affinity for aggregated forms of α-synuclein and a low affinity for monomeric forms of α-synuclein. The antibodies are useful in the diagnosis of neurodegenerative diseases..
| Alpha-synuclein antibodies and uses thereof|
The invention describes antibodies having a high affinity for aggregated forms of α-synuclein and a low affinity for monomeric forms of α-synuclein. The antibodies are useful in the diagnosis of neurodegenerative diseases..
|Rapidly maturing fluroscent proteins and methods for using the same|
Nucleic acid compositions encoding rapidly maturing fluorescent proteins, as well as non-aggregating versions thereof (and mutants thereof) as well as the proteins encoding the same, are provided. The proteins of interest are proteins that are fluorescent, where this feature arises from the interaction of two or more residues of the protein.
|Antibodies to cd70|
The present invention relates to antibodies and antigen binding fragments thereof which bind to the human cd70 protein with high affinity and display potent inhibition of tumour cell growth.. .
|Method of classifying antibody, method of identifying antigen, method of obtaining antibody or antibody set, method of constructing antibody panel and antibody or antibody set and use of the same|
The present invention relates to an isolated antibody against her1, an isolated antibody against cd147, an isolated antibody against cd73, and an isolated antibody against epcam; reagents and compositions including said antibodies; and uses of said reagents, compositions, and antibodies. The present invention also relates to nucleic acids and vectors expressing said antibodies.
|Mouse anti-aggrus monoclonal antibodies|
The present invention provides a monoclonal antibody or a functional fragment thereof, capable of recognizing aggrus epitope comprising an amino-acid sequence represented by a sequence id 1, 3, or 4, and the monoclonal antibody or the functional fragment thereof produced from a hybridoma with deposit id of ferm bp-11446, ferm bp-11447, ferm bp-11448 or ferm bp-11449. The present invention provides the hybridoma, and further an aggrus-clec-2 binding inhibitor and a pharmaceutical composition for inhibition of platelet aggregation, prevention of cancer metastasis, or treatment of tumor or cancer, comprising the monoclonal antibody or the functional fragment thereof..
|Identification of antigen-specific adaptive immune responses using arm-pcr and high-throughput sequencing|
Disclosed is a method for correlating at least one amino acid sequence from an antibody isolated from human or animal blood with at least one dna sequence corresponding to the antibody in the immunorepertoire of the human or animal. The method also provides a means for pairing heavy and light chains to produce synthesized monoclonal antibodies..
|Immunoglobulin fc polypeptides|
Methods and compositions involving polypeptides having an aglycosylated antibody fc domain. In certain embodiments, polypeptides have an aglycosylated fc domain that contains one or more substitutions compared to a native fc domain.
|Ultra-sensitive detection of analytes|
The present invention provides devices and methods for ultra-sensitive detection of analytes of interest in a rapid and convenient manner. A portable handheld device having replaceable cartridges adaptable for detection of a wide array of analytes (e.g., biological, environmental, and the like) is provided.
|Heterologous intron within an immunoglobulin domain|
The invention concerns the field of recombinant gene engineering. It concerns novel introns and compositions comprising such introns as well as a method to improve expression of polypeptides from nucleic acids such as cloned genes with heterologous introns, especially genes encoding antibodies and antibody derived fragments, and the production of various polypeptides in eukaryotic host cells using said novel intron sequences as heterologous introns..
|Method for detecting a beta-specific antibodies in a biological sample|
Disclosed is a method for detecting aβ-specific antibodies in a biological sample comprising the following steps:—contacting the sample with aβ-aggregates or with particles comprising aβ-aggregate like surfaces and allowing the aβ-specific antibodies to bind to the aβ-aggregates, and -detecting the aβ-specific antibodies bound to the aβ-aggregates by a single particle detection technique, preferably by fluorescence activated cell sorting facs.. .
|Method and system for detection of natural high intensity sweeteners that contain hydroxyl groups|
The present invention provides a hapten derivative and conjugate of a natural high intensity sweetener containing hydroxyl groups. The conjugate can be used to produce antibodies specific against the natural high intensity sweetener.
|Target of the phosphoinositide 3-kinase pathway|
The present disclosure generally relates to tyrosine phosphorylation sites of an akt enhancer, and methods for the detection of the phosphorylated tyrosine residues. In particular, anti-phosphotyrosine antibodies and binding proteins find use in the compositions and methods of the present disclosure..
|Antibodies specific to heterodimers of bcl-2 family and uses thereof|
Isolated antibodies specifically binding to heterodimers of the bcl-2 family and uses thereof for detecting presence of bcl-2 heterodimers in a patient.. .
|Polypeptides from non-typeable haemophilus influenzae|
Polypeptides comprising non-typeable haemophilus influenzae (nthi) amino acid sequences. Over 2500 specific nthi proteins are disclosed.
|Infectious clones of torque teno virus|
The present invention is directed to novel nucleotide and amino acid sequences of torque teno virus (“ttv”), including novel genotypes thereof, all of which are useful in the preparation of vaccines for treating and preventing diseases in swine and other animals. Vaccines provided according to the practice of the invention are effective against multiple swine ttv genotypes and isolates.
|Anti-cd40 antibodies and uses thereof|
The present invention includes compositions and methods for the expression, secretion and use of novel compositions for use as, e.g., vaccines and antigen delivery vectors, to delivery antigens to antigen presenting cells. In one embodiment, the vector is an anti-cd40 antibody, or fragments thereof, and one or more antigenic peptides linked to the anti-cd40 antibody or fragments thereof, including humanized antibodies..
|Nkp46-mediated nk cell tuning|
The present invention relates to compounds (e.g. Antibodies) that specifically bind and inhibit nkp46.
|Therapeutic agent for use in a method of treating psoriasis or atopic dermatitis|
The present invention provides a therapeutic agent for psoriasis or atopic dermatitis, and comprises anti-staphylococcus aureus antibodies as the active ingredient. A therapeutic agent for psoriasis or atopic dermatitis is specifically provided.
|Novel hiv-2 isolate|
The invention provides a novel strain of hiv-2 capable of causing immunodeficiency. The invention also provides compositions comprising the nucleic acids and polypeptides characteristic of this hiv-2 virus, antibodies specific for this hiv-2 virus, methods of using these compositions, and methods of detecting hiv-2 virus..
|Human ctla-4 antibodies and their uses|
The present invention provides novel human sequence antibodies against human ctla-4 and methods of treating human diseases, infections and other conditions using these antibodies.. .
|Antibodies against the ectodomain of erbb3 and uses thereof|
The present invention provides a novel class of antibodies and antigen binding fragments thereof that bind the extracellular domain of erbb3 receptor and inhibit various erbb3 functions. For example, the antibodies and antigen binding fragments described herein are capable of binding to the receptor designated erbb3 and inhibiting egf-like ligand mediated phosphorylation of the receptor.
|Use of c-met protein for predicting the efficacy of anti-hepatocyte growth factor ("hgf") antibodies in esophageal and gastric cancer patients|
The present invention relates to use of the human met receptor (also known as “c-met”) for predicting the efficacy of inhibitors of the hgf-met pathway, and in particular, anti-hgf antibodies, in the treatment of esophageal and gastric cancer patients. The present invention also relates to methods and kits for predicting the usefulness of anti-hgf antibodies in the treatment of esophageal and gastric cancer..
|Adjuvant therapy for staphylococcal infection with enterotoxin specific mabs|
Antibodies to seb, fragments thereof, and compositions comprising such are provided. Therapies for staphylococcal infection are provided, as well as assays for identifying additional agents useful in such therapies.
|Compositions and methods for detecting tlr3|
The present invention relates to antibodies, antibody fragments, and derivatives thereof that specifically bind to tlr3 cell receptors present on the surface of cells. The invention also relates to hybridomas producing such antibodies; methods of making such antibodies; fragments, variants, and derivatives of the antibodies; pharmaceutical compositions comprising the same; methods of using the antibodies to detect tlr3 levels on the surface of cells, and the use of such antibodies and compositions for diagnostic or therapeutic purposes in subjects..
|Scfv antibodies which pass epithelial and/or endothelial layers|
Scfv antibodies which specifically bind selected antigens and are obtainable by a method comprising (i) selecting from a pool of soluble and stable antibody frameworks a soluble and stable framework matching best the framework of a non-human antibody against the antigen with a certain binding specificity, (ii) either providing said soluble and stable framework with cdrs that bind specifically to said antigen, or mutating the framework of said non-human antibody towards the sequence of said soluble and stable framework, to generate scfv antibodies, (iii) testing the generated antibody for solubility and stability, and testing the generated antibody for antigen binding, and (iv) selecting an scfv that is soluble, stable and binds to the antigen specifically. Also provided are pharmaceutical compositions comprising said scfv antibody, methods of treatment and diagnosis for diseases related to over expression of antigens that are specifically bound by said antibody..
|Antibodies against epidermal growth factor receptor (egfr) and uses thereof|
Anti-egfr antibodies, therapeutic compositions comprising combinations of anti-egfr antibodies, as well as methods for using such antibodies and compositions to treat egfr-related disorders (e.g., cancers), are disclosed.. .
|Inhibition of tumor metastasis|
The invention provides nrp2 antagonists, such as anti-nrp2 antibodies, and their use in the prevention and treatment of tumor metastasis.. .
|Therapeutic combinations of anti-cd20 and anti-gm-csf antibodies and uses thereof|
The present disclosure describes a pharmaceutical combination of an anti-cd20 antibody and an anti-gm-csf antibody. Said combinations are highly efficacious in the treatment of b cell malignancies and inflammatory disorders..
|Stable formulations of antibodies to human programmed death receptor pd-1 and related treatments|
The present invention relates to stable formulations of antibodies against human programmed death receptor pd-1, or antigen binding fragments thereof. The present invention further provides methods for treating various cancers and chronic infections with stable formulations of antibodies against human programmed death receptor pd-1, or antigen binding fragments thereof..
|Directed evolution and in vitro panning of virus vectors|
The present invention provides methods of achieving directed evolution of viruses by in vivo screening or “panning” to identify viruses comprising scrambled aav capsids having characteristics of interest, e.g., tropism profile and/or neutralization profile (e.g., ability to evade neutralizing antibodies). The invention also provides scrambled aav capsids and virus particles comprising the same..
|Methods of treating a tauopathy|
The present disclosure provides methods of treating a tauopathy, involving administering an anti-tau antibody. The present disclosure also provides anti-tau antibodies, and formulations comprising same, for use in the methods..
|Rationally-designed anti-mullerian inhibiting substance type ii receptor antibodies|
Methods for generating hybrid antibodies are provided.. .
|Chimeric and humanized anti-histone antibodies|
The present invention concerns chimeric or humanized antibodies or antigen-binding fragments thereof that comprise specific cdr sequences, disclosed herein. Preferably, the antibodies or fragments comprise specific heavy and light chain variable region sequences disclosed herein.
|Separation of acetylated proteins from unacetylated proteins|
The invention relates to a process for separating acetylated proteins from unacetylated proteins. In particular, the invention relates to a process of using multimodal chromatography to separate acetylated proteins from unacetylated proteins.
|Diagnostic use of prosomatostatin|
The present invention relates to a method for the diagnosis, prognosis, monitoring and risk assessment of disturbances of the gastrointestinal tract activity and/or function and/or disturbances of the nutritional condition, with the exception of somatostatinoma, in a patient comprising the steps of: providing a sample of a bodily fluid of a patient; determining the level of prosomatostatin 1-64 or fragments thereof in said sample; correlating the level of prosomatostatin 1-64 or fragments thereof to the diagnosis, prognosis and risk assessment of disturbances of the gastrointestinal tract activity and/or function and/or disturbances of the nutritional condition, with the exception of somatostatinoma, in said patient, wherein said fragments have a length of at least 6 amino acid residues. The invention also relates to an antibody and a kit containing at least two antibodies..
|Retroviral vector particles and methods for their generation and use|
The present invention relates to methods of host cell transduction utilising ecotropic retroviral vector particles. The retroviral vector particle may comprise an envelope of friend murine leukaemia virus, in particular the envelope encoded by molecular clone pvc-211 and the host cell may be engineered to recombinantly express the rec1 receptor.
|Purification of biological products by constrained cohydration chromatography|
Materials and methods for use of constrained cohydration agents in the purification of biological materials such as antibodies, viruses, cells, and cellular organelles in connection with convective chromatography, fluidized bed or co-precipitation applications.. .
|Biological systems for production of highest quality proteins|
Vaccines and therapeutic proteins, including polyclonal and monoclonal antibodies, must be maximally pure and stable in their most active native form. This is a requirement for their maximal efficacy, specificity and stability as well as for precluding immune responses against erroneous or damaged moieties.
Methods, compositions and kits are disclosed directed at posaconazole fragments, immunogens, signal generating moieties, antibodies that bind posaconazole and immunoassays for detection of posaconazole.. .
|Group a streptococcal m-related proteins and methods of use|
Immunogenic group a streptococcus m-related polypeptides and peptides and immunogenic compositions comprising these m-related polypeptides and peptides are provided herein that evoke cross-opsonic and cross-protective anti-gas and anti-sdse antibodies in animals. Also provided are preparations comprising immunogenic compositions that comprise m-related polypeptides, peptides, or fusion proteins and that further comprise at least one additional group a streptococcus immunogen, such as an m peptide or spa peptide..
|Method for removing immunosuppressive properties of hiv envelope glycoproteins|
The present invention concerns a method for removal of immunosuppressive effects of envelope glycoproteins derived from human immunodeficiency virus, such as for vaccination purposes and for generation of neutralizing antibodies to hiv. The invention further concerns vaccines and antibodies obtainable by the method, as well as the use of such vaccines and antibodies..
|Prolactin receptor binding proteins and uses thereof|
The present invention encompasses prlr binding proteins. Specifically, the invention relates to antibodies that are chimeric, cdr grafted and humanized antibodies.
|Anti-mcam antibodies and associated methods of use|
Described herein are anti-mcam antibodies and antigen binding fragments thereof that are capable of inhibiting the interaction between mcam and its ligand, a protein comprising a laminin α-4 chain. These anti-mcam antibodies and antigen binding fragments thereof may be useful for, for example, treating inflammatory conditions characterized by the infiltration of mcam-expressing cells into a site of inflammation in the body..
|Amyloid-beta binding proteins|
The present invention relates to amyloid-beta (aβ) binding proteins. Antibodies of the invention have high affinity to aβ(20-42) globulomer or any aβ form that comprises the globulomer epitope.
|Anti-axl antibodies and uses thereof|
The present invention relates to anti-axl antibodies and uses thereof in diagnostic and therapeutic methods. More particularly, the present invention relates to a monoclonal antibody having specificity for axl comprising an heavy chain variable region comprising seq id no:2 in the h-cdr1 region, seq id no:3 in the h-cdr2 region and seq id no:4 in the h-cdr3 region; and a light chain variable region comprising seq id no: 6 in the l-cdr1 region, seq id no:7 in the l-cdr2 region and seq id no:8 in the l-cdr3 region.
|Antibodies to human signal peptide-containing proteins|
The invention provides a human signal peptide-containing proteins (sigp) and polynucleotides which identify and encode sigp. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists.
|Methods of treating and diagnosing pancreatitis|
The present invention provides nucleotide and amino acid sequences that identify and encode novel expressed chemokines (panec-1 and panec-2) from human pancreas cells. The present invention also provides for antisense molecules to the nucleotide sequences which encode panec-1 and panec-2, expression vectors for the production of purified panec-1 and panec-2, antibodies capable of binding specifically to panec-1 and panec-2, hybridization probes or oligonucleotides for the detection of panec-1- or panec-2-encoding nucleotide sequences, genetically engineered host cells for the expression of panec-1 and panec-2, diagnostic tests for chemokine activation based on panec-1- and panec-2-encoding nucleic acid molecules and antibodies capable of binding specifically to the protein..
|Agents that engage antigen-presenting cells through dendritic cell asialoglycoprotein receptor (dc-asgpr)|
The present invention includes compositions and methods for making and using anti dc-asgpr antibodies that can, e.g., activate dcs and other cells.. .
|Bovine fusion antibodies|
Disclosed herein are immunoglobulin constructs comprising at least one immunoglobulin domain or fragment thereof; and a therapeutic polypeptide or derivative or variant thereof attached to or inserted into said immunoglobulin domain. Also provided are immunoglobulin constructs comprising a mammalian immunoglobulin heavy chain comprising at least a portion of a knob domain in the complementarity-determining region 3 (cdr3h) or fragment thereof; and a therapeutic polypeptide attached to or inserted into said knob domain of the cdr3h.
|Nogo receptor antagonists|
Disclosed are immunogenic nogo receptor-1 polypeptides, nogo receptor-1 antibodies, antigen-binding fragments thereof, soluble nogo receptors and fusion proteins thereof and nucleic acids encoding the same. Also disclosed are nogo receptor antagonist polynucleotides.
|Modified proteins and peptides|
The present disclosure relates to modified proteins and peptides that have reduced ability to bind to pre-existing antibodies. Such modified protein/peptide molecules can comprise c-terminal additions, extensions or tags and/or certain amino acid substitutions.
|Humanized anti-cmet antagonists|
The invention provides therapeutic anti-c-met antibodies, and compositions comprising and methods of using these antibodies.. .
|Monoclonal antibodies that neutralize anthrax protective antigen (pa) toxin|
The present invention relates to monoclonal antibodies that bind or neutralize anthrax protective antigen (pa) toxin. The invention provides such antibodies, fragments of such antibodies retaining anthrax pa toxin-binding ability, fully human or humanized antibodies retaining anthrax pa toxin-binding ability, and pharmaceutical compositions including such antibodies.
|Predictive biomarker for cancer treatment with adcc-enhanced antibodies|
The present invention is directed to methods for identifying which patients diagnosed with cancer will most benefit from treatment with an anti-cancer therapy comprising an adcc-enhanced antibody.. .
|Combination therapy of anti-her3 antibodies|
The present invention relates to the combination therapy of anti-her3 antibodies with certain anti-her antibodies.. .
|Antigen binding molecules that bind egfr, vectors encoding same, and uses thereof|
The present invention relates to antigen binding molecules (abms). In particular embodiments, the present invention relates to recombinant monoclonal antibodies, including chimeric, primatized or humanized antibodies specific for human egfr.
|Methods for identifying antibodies with reduced immunogenicity|
The disclosure describes methods of identifying a variant of a reference antibody with reduced immunogenicity as compared to the reference antibody. The disclosure further describes variants of a reference anti-tnf-α antibody having reduced immunogenicity as compared to the reference anti-tnf-α reference antibody..
|Stable formulations of antibodies to tslp|
The present invention relates to stable formulations of antibodies against human tslp, or antigen binding fragments thereof.. .
|Antibody-sn-38 immunoconjugates with a cl2a linker|
The present invention concerns improved methods and compositions for preparing sn-38 conjugates of proteins or peptides, preferably immunoconjugates of antibodies or antigen-binding antibody fragments. More preferably, the sn-38 is attached to the antibody or antibody fragment using a cl2a linker, with 1-12, more preferably 6 or less, most preferably 1-5 sn-38 moieties per antibody or antibody fragment.
|Anti-mucin antibodies for early detection and treatment of pancreatic cancer|
Described herein are compositions and methods of use of anti-pancreatic cancer antibodies or fragments thereof, such as murine, chimeric, humanized or human pam4 antibodies. The antibodies show novel and useful diagnostic characteristics, such as binding with high specificity to pancreatic and other cancers, but not to normal or benign pancreatic tissues and binding to a high percentage of early stage pancreatic cancers.
|Humanized anti-hla-dr antibodies|
The present invention concerns compositions and methods of use of humanized anti-hla-dr antibodies. In preferred embodiments, the antibodies induce apoptosis and inhibit proliferation of lymphoma cells without inducing cdc or adcc.